AU2019227813B2 - Neoantigen identification with pan-allele models - Google Patents

Neoantigen identification with pan-allele models Download PDF

Info

Publication number
AU2019227813B2
AU2019227813B2 AU2019227813A AU2019227813A AU2019227813B2 AU 2019227813 B2 AU2019227813 B2 AU 2019227813B2 AU 2019227813 A AU2019227813 A AU 2019227813A AU 2019227813 A AU2019227813 A AU 2019227813A AU 2019227813 B2 AU2019227813 B2 AU 2019227813B2
Authority
AU
Australia
Prior art keywords
allele
peptide
mhc
presentation
neoantigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019227813A
Other languages
English (en)
Other versions
AU2019227813A1 (en
Inventor
Thomas Francis Boucher
Brendan BULIK-SULLIVAN
Jennifer BUSBY
Mojca Skoberne
Roman YELENSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Project Corp
Original Assignee
Seattle Project Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Project Corp filed Critical Seattle Project Corp
Publication of AU2019227813A1 publication Critical patent/AU2019227813A1/en
Assigned to GRITSTONE BIO, INC. reassignment GRITSTONE BIO, INC. Request for Assignment Assignors: GRITSTONE ONCOLOGY, INC.
Application granted granted Critical
Publication of AU2019227813B2 publication Critical patent/AU2019227813B2/en
Priority to AU2024220070A priority Critical patent/AU2024220070A1/en
Assigned to SEATTLE PROJECT CORP. reassignment SEATTLE PROJECT CORP. Request for Assignment Assignors: GRITSTONE BIO, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
AU2019227813A 2018-02-27 2019-02-27 Neoantigen identification with pan-allele models Active AU2019227813B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024220070A AU2024220070A1 (en) 2018-02-27 2024-09-25 Neoantigen identification with pan-allele models

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636061P 2018-02-27 2018-02-27
US62/636,061 2018-02-27
PCT/US2019/019836 WO2019168984A1 (en) 2018-02-27 2019-02-27 Neoantigen identification with pan-allele models

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024220070A Division AU2024220070A1 (en) 2018-02-27 2024-09-25 Neoantigen identification with pan-allele models

Publications (2)

Publication Number Publication Date
AU2019227813A1 AU2019227813A1 (en) 2020-10-01
AU2019227813B2 true AU2019227813B2 (en) 2024-06-27

Family

ID=67806416

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019227813A Active AU2019227813B2 (en) 2018-02-27 2019-02-27 Neoantigen identification with pan-allele models
AU2024220070A Pending AU2024220070A1 (en) 2018-02-27 2024-09-25 Neoantigen identification with pan-allele models

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024220070A Pending AU2024220070A1 (en) 2018-02-27 2024-09-25 Neoantigen identification with pan-allele models

Country Status (10)

Country Link
US (1) US20200411135A1 (https=)
EP (1) EP3759131A4 (https=)
JP (1) JP7480064B2 (https=)
KR (2) KR102930070B1 (https=)
CN (2) CN119851752A (https=)
AU (2) AU2019227813B2 (https=)
CA (1) CA3091917A1 (https=)
IL (1) IL276839A (https=)
TW (1) TW202000693A (https=)
WO (1) WO2019168984A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
EP4028763A1 (en) * 2019-09-13 2022-07-20 Evaxion Biotech A/S Method for identifying t-cell epitopes
EP4055610A4 (en) 2019-11-05 2023-11-29 Personalis, Inc. ESTIMATION OF TUMOR PURITY FROM SINGLE SAMPLES
WO2021091541A1 (en) * 2019-11-05 2021-05-14 Kri Technologies Incorporated Identifying cancer neoantigens for personalized cancer immunotherapy
CN114929899B (zh) * 2020-01-07 2026-03-10 韩国科学技术院 一种新抗原的筛选方法、系统及其用途
EP4168569A4 (en) * 2020-06-18 2024-08-07 Personalis, Inc. Machine-learning techniques for predicting surface-presenting peptides
CN111798919B (zh) * 2020-06-24 2022-11-25 上海交通大学 一种肿瘤新抗原预测方法、预测装置及存储介质
WO2022013154A1 (en) * 2020-07-14 2022-01-20 Myneo Nv Method, system and computer program product for determining presentation likelihoods of neoantigens
EP4192941A1 (en) 2020-08-07 2023-06-14 Neogene Therapeutics B.V. Methods to enrich genetically engineered t cells
AU2021325082A1 (en) * 2020-08-13 2023-04-20 Biontech Us Inc. RAS neoantigens and uses thereof
WO2022047085A1 (en) * 2020-08-26 2022-03-03 NanoMosaic INC. Sensors for unbiased proteomic studies, method of manufacture and use thereof
CN112509641B (zh) * 2020-12-04 2022-04-08 河北环境工程学院 一种基于深度学习监测抗生素与金属联合产物的智能方法
WO2022121973A1 (zh) * 2020-12-09 2022-06-16 江苏恒瑞医药股份有限公司 基于机器学习的肽免疫原性预测、鉴别系统及方法
US12567480B2 (en) * 2021-01-19 2026-03-03 Amazon Technologies, Inc. Deep learning model for predicting tumor-specific neoantigen MHC class I or class II immunogenicity
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
KR102769935B1 (ko) * 2021-03-30 2025-02-19 한국과학기술원 펩타이드-mhc에 대한 t 세포 활성의 예측 방법 및 분석장치
CN113255690B (zh) * 2021-04-15 2022-04-12 南昌大学 一种基于轻量级卷积神经网络的复合绝缘子憎水性检测方法
WO2022224336A1 (ja) * 2021-04-20 2022-10-27 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
CA3216276A1 (en) 2021-04-29 2022-11-03 Yardena Samuels T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
CN113409888A (zh) * 2021-06-21 2021-09-17 中国科学院自动化研究所 一种肿瘤微环境及肿瘤基因突变检测系统、方法及设备
JP7627826B2 (ja) * 2021-08-10 2025-02-07 日本電気株式会社 情報処理システム及び情報処理方法
EP4148146A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate personalized neoantigens of a tumor of a patient
JP2024533501A (ja) 2021-09-13 2024-09-12 オンコディーエヌエー 患者の腫瘍の個別化された新生抗原を生成する方法
EP4413580A4 (en) 2021-10-05 2025-08-13 Personalis Inc PERSONALIZED TESTS FOR PERSONALIZED CANCER MONITORING
CA3246299A1 (en) * 2022-04-08 2023-10-12 Seattle Project Corp. ANTIGEN PREDICTIONS FOR EPITOPES DERIVED FROM INFECTIOUS DISEASES
CN114821176B (zh) * 2022-04-28 2022-11-01 浙江大学 一种儿童脑部mr图像病毒性脑炎分类系统
CN114997303B (zh) * 2022-05-30 2025-06-13 杭州电子科技大学 一种基于深度学习的膀胱癌代谢标志物筛选方法及系统
WO2024015892A1 (en) * 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
AU2023321890A1 (en) * 2022-08-12 2025-02-27 Biontech Us Inc. Methods and systems for prediction of hla epitopes
KR102694428B1 (ko) * 2023-02-01 2024-08-13 충남대학교산학협력단 데이터 증강 방법 및 이를 이용한 양성 에피토프 예측 모델 생성 방법
CN116580771A (zh) * 2023-02-20 2023-08-11 清华大学 预测肿瘤新抗原的方法和装置
CN116469457B (zh) * 2023-06-14 2023-10-13 普瑞基准科技（北京）有限公司 Mhc与抗原多肽结合、呈递及免疫原性的预测模型训练方法和装置
CN116453599B (zh) * 2023-06-19 2024-03-19 深圳大学 开放阅读框预测方法、设备及存储介质
WO2025160446A1 (en) * 2024-01-25 2025-07-31 Ai Proteins, Inc. Methods and systems for characterizing structural features of a protein

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
DE69133064T2 (de) 1990-02-26 2003-03-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Identifizierung und expression von insekten-steroidrezeptor-dns-sequenzen
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
JP5031967B2 (ja) 2000-03-22 2012-09-26 イントレキソン コーポレーション 新規エクジソン受容体ベースの誘導性遺伝子発現系
US6931351B2 (en) * 2001-04-20 2005-08-16 International Business Machines Corporation Decision making in classification problems
ES2341802T3 (es) * 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3194970B1 (en) * 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016069282A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
JP2019506143A (ja) 2015-12-14 2019-03-07 ベリカム ファーマシューティカルズ， インコーポレイテッド 治療用細胞の活性化及び排除のための二重コントロール
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов

Also Published As

Publication number Publication date
US20200411135A1 (en) 2020-12-31
CN111868080B (zh) 2024-11-29
AU2024220070A1 (en) 2024-10-17
CN111868080A (zh) 2020-10-30
IL276839A (en) 2020-10-29
JP2021514671A (ja) 2021-06-17
WO2019168984A1 (en) 2019-09-06
CN119851752A (zh) 2025-04-18
KR20200127001A (ko) 2020-11-09
JP7480064B2 (ja) 2024-05-09
AU2019227813A1 (en) 2020-10-01
KR102930070B1 (ko) 2026-02-24
TW202000693A (zh) 2020-01-01
CA3091917A1 (en) 2019-09-06
WO2019168984A8 (en) 2020-06-04
EP3759131A1 (en) 2021-01-06
KR20260041858A (ko) 2026-03-27
EP3759131A4 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
AU2019227813B2 (en) Neoantigen identification with pan-allele models
US20220148681A1 (en) Neoantigen identification using hotspots
AU2025279629A1 (en) Neoantigen identification for T-cell therapy
US20220154281A1 (en) Identification of neoantigens with mhc class ii model
HK40129773A (en) Neoantigen identification using hotspots
HK40034414B (en) Neoantigen identification using hotspots
HK40034414A (en) Neoantigen identification using hotspots

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GRITSTONE BIO, INC.

Free format text: FORMER APPLICANT(S): GRITSTONE ONCOLOGY, INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SEATTLE PROJECT CORP.

Free format text: FORMER OWNER(S): GRITSTONE BIO, INC.